The Anatolian Journal of Cardiology
Original Investigation

Maternal and Fetal Outcomes in Pregnant Women with Pulmonary Arterial Hypertension: A Single-Center Experience and Review of Current Literature

1.

Department of Cardiology, University of Health Sciences, Koşuyolu Heart Training and Research Hospital, İstanbul, Turkey

2.

Department of Cardiology, Faculty of Medicine, Medipol University, İstanbul, Turkey

3.

Department of Biostatistics, Faculty of Medicine, Nisantaşı University, İstanbul, Turkey

Anatol J Cardiol 2022; 26: 902-913
DOI: 10.5152/AnatolJCardiol.2022.1762
Read: 64 Downloads: 40 Published: 01 December 2022

Background: Although pregnancy in women with pulmonary arterial hypertension has been considered a high-risk condition, current data regarding pregnancy with pulmonary arterial hypertension are scarce. In this study, we aimed to evaluate our single-center data on maternal and fetal outcomes in pregnant women with PAH and review currently available risk-based management strategies.

Methods: Our single-center study group comprised 35 women who became pregnant after the diagnosis of pulmonary arterial hypertension or in whom pulmonary arterial hypertension was diagnosed within early post-partum period. Clinical, laboratory, echocardiographic, and hemodynamic characteristics of pregnant and non-pregnant productive women with pulmonary arterial hypertension were compared, and similar comparison was also repeated for survivors and non-survivors in pregnant patient group.

Results: Pregnancy was noted in 15% of the 228 females with pulmonary arterial hypertension who were of hormonally productive ages, generally well-tolerated until delivery. Elective abortion and pre-term delivery were documented in 1 (2.8%) and 12 (35.3%) pregnant women, respectively. Switching to sildenafil was the standard medication during pregnancy. Cesarian section was the preferred method of delivery in all pregnant women with pulmonary arterial hypertension and was performed without any complication. Clinic deteoriation within the first week of delivery was observed in 5 (41.6%) patients. Maternal mortality was noted in 13 (37.1%) patients and was documented to cumulate within the first month of delivery. However, any sign predicting post-partum clinical deterioration was not found. No fetal mortality was observed.

Conclusion: Despite the development of advanced therapies, pregnancy in pulmonary arterial hypertension still carries a high mortality risk and requires multi-disciplinary expert center care with more proactive management strategies.

Cite this article as: Tokgöz HC, Akbal ÖY, Karagöz A, et al. Maternal and fetal outcomes in pregnant women with pulmonary arterial hypertension: A single-center experience and review of current literature. Anatol J Cardiol. 2022;26(12):902-913.

Files
ISSN 2149-2263 EISSN 2149-2271